For research use only. Not for therapeutic Use.
A small molecule inhibitor of multi-CDK, which inhibits CDK 1, 2 , 4, 5, 6, and 9 in vitro and induces apoptosis in multiple myeloma via GSK-3β activation and RNA polymerase II inhibition
| Catalog Number | I022588 |
| CAS Number | 902135-89-1 |
| Molecular Formula | C16H17Cl2N5O2.CH4O3S |
| Purity | ≥95% |
| IUPAC Name | 4-[(2,6-dichlorobenzoyl)amino]-N-piperidin-4-yl-1H-pyrazole-5-carboxamide;methanesulfonic acid |
| InChI | InChI=1S/C16H17Cl2N5O2.CH4O3S/c17-10-2-1-3-11(18)13(10)15(24)22-12-8-20-23-14(12)16(25)21-9-4-6-19-7-5-9;1-5(2,3)4/h1-3,8-9,19H,4-7H2,(H,20,23)(H,21,25)(H,22,24);1H3,(H,2,3,4) |
| SMILES | CS(=O)(=O)O.C1CNCCC1NC(=O)C2=C(C=NN2)NC(=O)C3=C(C=CC=C3Cl)Cl |
| Reference | L Sato et al. AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3β activation and RNA polymerase II inhibition. Oncogene 2010, 29, 2325-2336.
MS Squires et al. AT7519, a cyclin-dependent kinase inhibitor, exerts its effects by transcriptional inhibition in leukemia cell lines and patient samples. Mol. Cancer Ther. 2010, 9(4), 920-928. |
